Advisory Committee on the Medical Uses of Isotopes; Renewal Notice, 14959 [E6-4286]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 57 / Friday, March 24, 2006 / Notices
Nicholas G. Trikouros, U.S. Nuclear
Regulatory Commission, Washington,
DC 20555–0001.
All correspondence, documents, and
other materials shall be filed with the
administrative judges in accordance
with 10 CFR 2.202.
Issued at Rockville, Maryland, this 16th
day of March 2006.
G. Paul Bollwerk, III,
Chief Administrative Judge, Atomic Safety
and Licensing Board Panel.
[FR Doc. E6–4276 Filed 3–23–06; 8:45 am]
Advisory Committee on the Medical
Uses of Isotopes; Renewal Notice
U. S. Nuclear Regulatory
Commission.
ACTION: This notice is to announce the
renewal of the Advisory Committee on
the Medical Uses of Isotopes (ACMUI)
for a period of two years.
AGENCY:
The U.S.
Nuclear Regulatory Commission (NRC)
has determined that the renewal of the
charter for the Advisory Committee on
the Medical Uses of Isotopes for the two
year period commencing on March 17,
2006 is in the public interest, in
connection with duties imposed on the
Commission by law. This action is being
taken in accordance with the Federal
Advisory Committee Act, after
consultation with the Committee
Management Secretariat, General
Services Administration.
The purpose of the ACMUI is to
provide advice to NRC on policy and
technical issues that arise in regulating
the medical use of byproduct material
for diagnosis and therapy.
Responsibilities include providing
guidance and comments on current and
proposed NRC regulations and
regulatory guidance concerning medical
use; evaluating certain non-routine uses
of byproduct material for medical use;
and evaluating training and experience
of proposed authorized users. The
members are involved in preliminary
discussions of major issues in
determining the need for changes in
NRC policy and regulation to ensure the
continued safe use of byproduct
material. Each member provides
technical assistance in his/her specific
area(s) of expertise, particularly with
respect to emerging technologies.
Members also provide guidance as to
NRC’s role in relation to the
responsibilities of other Federal
SUPPLEMENTARY INFORMATION:
wwhite on PROD1PC61 with NOTICES
1 Attachment A contains sensitive unclassified
information and will not be released to the public.
2 Attachment B contains Safeguards Information
and will not be released to the public.
of
Nuclear Material Safety and Safeguards,
U.S. Nuclear Regulatory Commission,
Washington, DC 20555; Telephone (301)
415–7608; e-mail mss@nrc.gov.
NUCLEAR REGULATORY
COMMISSION
18:26 Mar 23, 2006
The Licensees identified in
Attachment A 1 to this Order hold
licenses issued by the U.S. Nuclear
Regulatory Commission (NRC or
Commission) or an Agreement State, in
accordance with the Atomic Energy Act
of 1954, as amended, and 10 CFR parts
30, 32, 50, 70 and 71, or equivalent
Agreement State regulations. The
licenses authorize them to possess and
transfer items containing radioactive
material quantities of concern. This
Order is being issued to all such
Licensees who may transport
radioactive material quantities of
concern under the NRC’s authority to
protect the common defense and
security, which has not been
relinquished to the Agreement States.
The Orders require compliance with
specific additional security measures to
enhance the security for transport of
certain radioactive material quantities of
concern.
On September 11, 2001, terrorists
simultaneously attacked targets in New
York, NY, and Washington, DC,
utilizing large commercial aircraft as
weapons. In response to the attacks and
intelligence information subsequently
obtained, the Commission issued a
number of Safeguards and Threat
Advisories to Licensees in order to
strengthen Licensees’ capabilities and
readiness to respond to a potential
attack on this regulated activity. The
Commission has also communicated
with other Federal, State and local
government agencies and industry
representatives to discuss and evaluate
the current threat environment in order
to assess the adequacy of the current
security measures. In addition, the
Commission commenced a
comprehensive review of its safeguards
and security programs and
requirements.
As a result of its initial consideration
of current safeguards and security
requirements, as well as a review of
information provided by the intelligence
community, the Commission has
determined that certain security
measures are required to be
implemented by Licensees as prudent,
interim measures to address the current
threat environment in a consistent
manner. Therefore, the Commission is
imposing requirements, as set forth in
Attachment B 2 of this Order, on all
Licensees identified in Attachment A of
this Order. These additional security
measures, which supplement existing
regulatory requirements, will provide
the Commission with reasonable
assurance that the common defense and
security continue to be adequately
protected in the current threat
environment. These additional security
measures will remain in effect until the
Commission determines otherwise.
The Commission recognizes that
Licensees may have already initiated
many of the measures set forth in
Attachment B to this Order in response
to previously issued Safeguards and
Threat Advisories or on their own. It is
also recognized that some measures may
not be possible or necessary for all
shipments of radioactive material
quantities of concern, or may need to be
tailored to accommodate the Licensees’
specific circumstances to achieve the
intended objectives and avoid any
unforeseen effect on the safe transport of
radioactive material quantities of
concern.
Although the security measures
implemented by Licensees in response
to the Safeguards and Threat Advisories
have been adequate to provide
reasonable assurance of adequate
protection of common defense and
FOR FURTHER INFORMATION PLEASE
CONTACT: Mohammad S. Saba, Office
BILLING CODE 7590–01–P
VerDate Aug<31>2005
agencies as well as of various
professional organizations and boards.
Members of this Committee have
demonstrated professional
qualifications and expertise in both
scientific and non-scientific disciplines
including nuclear medicine; nuclear
cardiology; radiation therapy; medical
physics; nuclear pharmacy; State
medical regulation; patient’s rights and
care; health care administration; and
Food and Drug Administration
regulation.
Jkt 208001
14959
Dated: March 17, 2006.
Andrew L. Bates,
Federal Advisory Committee, Management
Officer.
[FR Doc. E6–4286 Filed 3–23–06; 8:45 am]
BILLING CODE 7590–01–P
NUCLEAR REGULATORY
COMMISSION
[EA–05–006]
In the Matter of Certain Licensees
Authorized To Possess and Transfer
Items Containing Radioactive Material
Quantities of Concern; Order Imposing
Additional Security Measures
(Effective Immediately)
PO 00000
Frm 00128
Fmt 4703
Sfmt 4703
E:\FR\FM\24MRN1.SGM
24MRN1
]]>Agencies
[Federal Register Volume 71, Number 57 (Friday, March 24, 2006)]
[Notices]
[Page 14959]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-4286]
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Advisory Committee on the Medical Uses of Isotopes; Renewal
Notice
AGENCY: U. S. Nuclear Regulatory Commission.
ACTION: This notice is to announce the renewal of the Advisory
Committee on the Medical Uses of Isotopes (ACMUI) for a period of two
years.
-----------------------------------------------------------------------
SUPPLEMENTARY INFORMATION: The U.S. Nuclear Regulatory Commission (NRC)
has determined that the renewal of the charter for the Advisory
Committee on the Medical Uses of Isotopes for the two year period
commencing on March 17, 2006 is in the public interest, in connection
with duties imposed on the Commission by law. This action is being
taken in accordance with the Federal Advisory Committee Act, after
consultation with the Committee Management Secretariat, General
Services Administration.
The purpose of the ACMUI is to provide advice to NRC on policy and
technical issues that arise in regulating the medical use of byproduct
material for diagnosis and therapy. Responsibilities include providing
guidance and comments on current and proposed NRC regulations and
regulatory guidance concerning medical use; evaluating certain non-
routine uses of byproduct material for medical use; and evaluating
training and experience of proposed authorized users. The members are
involved in preliminary discussions of major issues in determining the
need for changes in NRC policy and regulation to ensure the continued
safe use of byproduct material. Each member provides technical
assistance in his/her specific area(s) of expertise, particularly with
respect to emerging technologies. Members also provide guidance as to
NRC's role in relation to the responsibilities of other Federal
agencies as well as of various professional organizations and boards.
Members of this Committee have demonstrated professional
qualifications and expertise in both scientific and non-scientific
disciplines including nuclear medicine; nuclear cardiology; radiation
therapy; medical physics; nuclear pharmacy; State medical regulation;
patient's rights and care; health care administration; and Food and
Drug Administration regulation.
FOR FURTHER INFORMATION PLEASE CONTACT: Mohammad S. Saba, Office of
Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory
Commission, Washington, DC 20555; Telephone (301) 415-7608; e-mail
mss@nrc.gov.
Dated: March 17, 2006.
Andrew L. Bates,
Federal Advisory Committee, Management Officer.
[FR Doc. E6-4286 Filed 3-23-06; 8:45 am]
BILLING CODE 7590-01-P
